Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that R343, an inhaled SYK inhibitor being evaluated as a potential therapeutic for patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE